Please login to the form below

Not currently logged in
Email:
Password:

antibiotics

This page shows the latest antibiotics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan

Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan

FDA Commissioner Scott Gottlieb published proposals to entice industry investment in antibiotic R&D last month, while the EU and WHO are also funding collaborative initiatives.

Latest news

More from news
Approximately 53 fully matching, plus 305 partially matching documents found.

Latest Intelligence

  • Rules of engagement Rules of engagement

    A 2015 survey by the World Health Organization (WHO) in 12 countries highlighted people’s unfamiliarity with the language of antibiotic resistance. ... Only one-fifth were aware of its abbreviated form  ‘AMR’. By contrast, more than two-thirds

  • No incentive for a cure No incentive for a cure

    The stakes are too high for this not to happen. The risk we face from antimicrobial resistance and the current lack of new antibiotics tells us all we need to know

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    No new classes of antibiotics have been introduced for more than 30 years and antibiotic patent applications worldwide. ... But PUSH incentives are not enough to fix the problem with the antibiotics market.

  • Health on instalment Health on instalment

    The only apt parallel might be the discovery of antibiotics or vaccines, but even those milestones may end up paling in comparison.

  • Significant figures Significant figures

    us.”. An inhaled formulation of last-resort antibiotic Amikacin, ALIS taps into a need for new antibiotics as well as industry heads towards more joined-up thinking to tackle antimicrobial resistance. ... European physicians welcome the development of

More from intelligence
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Nabriva Therapeutics appoints new chief commercial officer. Francesco Maria Lavino joins to support commercialisation of its new antibiotic. ... He said: “Nabriva Therapeutics is poised to introduce what is potentially the first new class of

  • Destiny Pharma appoints new CEO Destiny Pharma appoints new CEO

    development. He said: “The resistance to antibiotics is becoming a global issue that needs to be addressed and I believe Destiny has a significant part to play.

  • Dr Engelbert Tjeenk Willink joins Allecra Therapeutics Dr Engelbert Tjeenk Willink joins Allecra Therapeutics

    Regulatory authorities have recognised the potential that Allecra’s novel antibiotic may contribute towards solving the crisis of resistant bacterial infections, and out lead development programme has been significantly expedited. ... With these new

  • Micreos appoints chief medical officer Micreos appoints chief medical officer

    In his new role Dr Frieling will be responsible for overseeing Micreos' antibiotic alternative, Staphefekt, as it begins clinical trials.

  • Nabriva Therapeutics adds Will Sargent to team Nabriva Therapeutics adds Will Sargent to team

    He said: “ I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need. “

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • Antibiotic Resistance: Alarm bells ring louder than ever

    where antibiotics and the threat of antimicrobial resistance (AMR) became a hot topic in the mainstream media. ... 1. Prevent the need for antibiotics.Immunisation programmes engender immunity and make people less susceptible to pathogens.

  • Longevity but at what price?

    Zhavoronkov’ s theory is that by following the advances in biomedical research, we can now vaccinate against what were once killer illnesses; antibiotics have increased our life expectancy (although there is

  • Adelphi Research UK Welcomes Six New Starters

    She has carried out exchange programmes in China and Hong Kong and has also completed two research internships in novel antibiotic discovery.

  • Virtual reality—a change for the better in medical education

    keeps insisting that her mother be prescribed antibiotics despite inconclusive evidence that antibiotics are necessary. ... The responses of medical general practitioners to unreasonable patient demand for antibiotics— a study of medical ethics using

  • How to be a patient

    They realise there is not a pill for every ill, so they don't demand an antibiotic for every infection or expect to walk out with a prescription after every consultation.

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics